Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech

Jul 11, 2022 1 min read
Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech

Originally published by STAT on June 28, 2022

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline.

Cognito, based in Cambridge, Mass., is developing a headset that feeds a patient light and sound to drive changes in the brains of people with Alzheimer’s disease and other neurological conditions. Cognito will use the new funding from Menlo Park-based FoundersX to complete clinical trials it can submit to the Food and Drug Administration for approval. And with its new Silicon Valley connections comes a techy confidence that the company is sitting on a potential gold mine of data that could lead to a better understanding of the brain and how to treat the diseases that damage it.

Great! Next, complete checkout for full access to Agetech News.
Welcome back! You've successfully signed in.
You've successfully subscribed to Agetech News.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.